BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease

BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in a Phase 1 (Ph1), open-label ... read more
Source: Bing NewsPublished on 2021-06-08